

## Compulsory redemption of minority shares and application for delisting

Greiner Bio-One GmbH ("GBO") has notified the board of directors of Vigmed Holding AB (publ) ("Vigmed") that GBO owns more than 90 percent of the shares in Vigmed. Furthermore, GBO has requested compulsory redemption of the remaining shares in Vigmed.

On account GBO owning more than 90 percent of the shares in Vigmed and having requested compulsory redemption of the remaining shares in Vigmed, the board of directors of Vigmed has decided to apply for delisting of the Vigmed shares from Nasdaq First North. Further information about the delisting will be communicated as soon as possible.

### For more information

CEO Henrik Olsen, tel. +46 763-497 364

Board member Georg Heftberger, tel. +43 664 884 106 83

This information was submitted for publication, through the agency of the contact persons set out above, at 8:00 a.m. CET on 6 July 2017.

*Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed's share is traded on Nasdaq First North in Stockholm (ticker VTG). Remium Nordic AB is the Company's Certified Advisor. Additional information about the company can be found on Vigmed's website: [www.vigmed.com/investor](http://www.vigmed.com/investor)*